V. Yu. Kosyrev

V. Yu. Kosyrev

Auto-generated profile, based on publicly available information

V. Yu. Kosyrev

N.N. Blokhin National Medical Research Center of Oncology; I.M. Sechenov First Moscow State Medical University

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
NLN. V. Lyubimova
N. V. Lyubimova
VKV. Yu. Kosyrev
V. Yu. Kosyrev
YPYu. I. Patyutko
Yu. I. Patyutko
NKN. E. Kushlinskii
N. E. Kushlinskii

15 March 2022 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
MLM. S. Lebedko
M. S. Lebedko
SGS. S. Gordeev
S. S. Gordeev
SGS. G. Gaydarov
S. G. Gaydarov
ZMZ. Z. Mamedli
Z. Z. Mamedli
VKV. Yu. Kosyrev
V. Yu. Kosyrev
SKS. O. Kochkina
S. O. Kochkina
Background. Colorectal anastomotic leakage remains on of the most significant challenges in rectal surgery.Objective: to assess the impact of pelvic peritoneal floor reconstruction on the incidence of postoperative complications associated with colorectal anastomosis.Materials and methods. In this retrospective cohort study, we analyzed medical records of rectal cancer patients who had undergone rectal resection with anastomosis formation between 2013 and 2020. we compared patients who had no pelvic peritoneal floor reconstruction (from 2013 to 2017) and those who had it (2018–2020). Only patients with favorable prognosis (tumor located at least 5 cm above the transitional anal fold and no history of chemoradiotherapy) were included. The primary outcome measure was the incidence of peritonitis and colorectal anastomosis leakage. Secondary outcome measures included overall incidence of complications (Clavien–Dindo), mortality rate, blood loss, and duration of surgery.Results. A total of 120 patients were included into the experimental group, while the control group was composed of 125 patients. Ten patients from the control group developed peritonitis (8.0 %), whereas in the experimental group, there were no cases of peritonitis (p = 0.002). Anastomotic leakage was registered in 12 individuals from the experimental group (12.5 %) and 14 controls (11.2 %) (p = 0.753). The overall incidence of postoperative complications was 23.3 % (n = 28) among patients who had pelvic peritoneal floor reconstruction and 18.4 % (n = 23) among those who did not have it (p = 0.342). Colostomy was required in 92 patients from the experimental group (76.7 %) and 78 patients from the control group (62.4 %) (p = 0.018). The postoperative mortality was 0.8 % in the control group (n = 1) and 0 % in the experimental group (p = 1).Conclusion. Pelvic peritoneal floor reconstruction reduces the risk of peritonitis, but does not affect the overall risk of anastomotic leakage. This method is effective for the prevention of severe postoperative complications.

1 January 2016 in Journal of radiology and nuclear medicine
Verified
Journal Article
Open access
PDF file
BDB. I. Dolgushin
B. I. Dolgushin
VKV. Yu. Kosyrev
V. Yu. Kosyrev
DMD. V. Martynkov
D. V. Martynkov
LDL. V. Demidov
L. V. Demidov
NSN. A. Shishkina
N. A. Shishkina
VNV. V. Nazarova
V. V. Nazarova
Трансартериальная химиоэмболизация при метастазах увеальной меланомы в печени

12 April 2021 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
VBV. V. Breder
V. V. Breder
MPM. Y. Pitkevich
M. Y. Pitkevich
VKV. Y. Kosirev
V. Y. Kosirev
BDB. I. Dolgushin
B. I. Dolgushin
EVE. R. Virshke
E. R. Virshke
KLK. K. Laktionov
K. K. Laktionov
Hepatocellular carcinoma (HCC) remains the fourth leading cause of cancer-related death in the world. The progression of HCC after previously effective TACE is quite often local. This article describes our experience with repeated TACE in patients with local progression of HCC. We analyzed 125 patients with HCC, for the period from 2009 to 2015. TACE was performed for intrahepatic manifestations of HCC. Progression of HCC after TACE-1 was observed in 88.8 % (n = 111) patients. Disease progression after TACE‑2 was registered in 40 (32 %) patients. TACE‑3 was performed in 8 (6.4 %) patients. The analysis showed that isolated local intrahepatic progression of HCC with the growth of intrahepatic tumor nodes previously subjected to TACE‑1 (without new foci) does not affect OS. The efficiency of re-embolization (TACE‑2) is somewhat lower than for TACE of the first stage. Independent factors of overall survival increase in patients receiving TACE: satisfactory objective status according to ECOG, efficacy of the first stage of TACE, late progression and objective effect after re-embolization.

10 December 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
APA. A. Pitkevich
A. A. Pitkevich
VKV. Yu. Kosyrev
V. Yu. Kosyrev
IDI. A. Dzhanyan
I. A. Dzhanyan
MNM. S. Novruzbekov
M. S. Novruzbekov
AMArtem Monakhov
Artem Monakhov
МПМ. Ю. Питкевич
М. Ю. Питкевич
Introduction. Liver transplant (LT) is a widely accepted treatment for hepatocellular carcinoma (HCC). The role of neoadjuvant (NAT) is still under debate.The aim of the work is to assess the effect of NAT on relapse-free survival (RFS) and overall survival (OS) in patients with HCC who underwent LT.Methods and materials. 63 patients diagnosed with HCC were observed at Blokhin National Medical Research Center of Oncology from October 2010 to January 2020. Of these, 28 patients did not receive any type of treatment before transplantation, 35 patients received various types of NAT. Two groups had similar patient and tumour characteristics at baseline. A significant number of patients with decompensated cirrhosis were observed in the non-NAT group (n = 14; 50%), while no patients with CP-C liver cirrhosis were observed in the NAT group (n = 0; 0%; p = 0.000). The average wait for a liver transplant was 10.3 months in the NAT group and 6.8 months in the NAT-free group (p = 0.561).Results. In the bridging subgroup, the tumour progression was detected in 29% of patients, stable disease in 47% of patients, partial response was achieved in 14% of patients, complete tumour response was observed in 5%. For 5% of patients, it was not possible to estimate the effect of the therapy due to the lack of appropriate data archives. In the subgroup of downstaging therapy, the tumour progression was detected in 23% of patients, stable disease in 41% of patients, a partial response was achieved in 12% of patients, a complete tumour response was observed in 6%. The treatment allowed the Milan criteria to be fulfilled in 18% of patients.Conclusion. There was no difference in overall survival (OS) or disease-free survival (DFS) between the NAT and control groups.

29 June 2025 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
DMD. V. Martynkov
D. V. Martynkov
VKV. Y. Kosirev
V. Y. Kosirev
VNV. V. Nazarova
V. V. Nazarova
LDL. V. Demidov
L. V. Demidov
IPI. V. Pogrebnyakov
I. V. Pogrebnyakov
ДФД. Ю. Францев
Д. Ю. Францев
Purpose: To evaluate the tolerability and efficacy of transarterial chemoembolization (TACE) in the treatment of patients with metastatic liver disease from uveal melanoma. Materials and methods: From 2000 to 2024, 131 patients with uveal melanoma underwent liver TACE for metastatic liver disease at the N.N. Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health. The treatment was carried out for multiple bilobar liver disease (110 patients) and solitary/single liver metastases (21 patients). A total of 283 TACEs were performed. The duration of observation after TACE ranged from 1 to 152 months. The median observation was 11 months. Results: TACE was technically successful in 100 % of cases. Postembolization syndrome of varying severity was observed in 82.4 %. Mortality 0 %. Local response (according to mRECIST) was observed in 75/131 (57.2 %) patients. Overall survival (OS) (n=131) was: 1-year — 78.5 %, 2-year — 47 %, %, 3-year — 17 %. Median overall survival was 23 months. In the group of patients who received only TACE (n=29): 1-year OS — 66 %, 2-year OS — 27 %, 3-year OS — 13 %. In the TACE + additional treatment group (n=102) — 1-year OS — 82.2 %, 2-year OS — 50.3 %, 3-year OS — 23.7 %. Conclusions: TACE is a safe treatment option for patients with uveal melanoma with different volumes of liver metastases. Local response in slightly more than half of patients indicates the need for a more rigorous definition of indications for this intervention. Ourresults with TACE indicate the need for further research to determine the optimal timing of the combination of regional interventional treatment with systemic drug therapy, surgery, and liver chemoperfusion.